We are pleased to report that yesterday the U.S. House of Representatives passed a bill, H.R. 184 – The Protect Medical Innovation Act of 2017, by an overwhelming vote of 283 to 132 with 57 Democrats joining 226 Republicans in support. Thank you to all of the members of Ohio’s delegation to the U.S. House who supported this legislation.

The permanent repeal of the Medical Device Tax has been a top policy priority of BioOhio since it took effect as part of the Affordable Care Act (colloquially known as Obamacare) in 2010. Since that time, we have worked continually with both AdvaMed and MDMA, alongside our government relations firm, G2G, to ensure our federal delegation understands the effect this 2.3% excise tax would have slowing growth and innovation in the medical device industry, and ultimately on the patients that benefit from these life-saving technologies. Through regular meetings on Capitol Hill, multiple BioOhio support letters signed by many of you over the years, legislative roundtables in Columbus, and medical device manufacturer tours for our Members of Congress, the repeal of this tax enjoys broad, bi-partisan support in Congress. 11 of Ohio’s 15 members of the House of Representatives were co-sponsors of this legislation.

While the path to passage in the U.S. Senate is uncertain, this is an important step in permanently repealing this destructive tax. I want to thank all of the BioOhio members and the entire bioscience industry who have been engaged on this issue and advocated for its repeal. We will continue to work with you and our two Senators to move this bill closer to being signed into law.

In the meantime, if you have any questions on this or any of our advocacy efforts, please do not hesitate to contact me.

Thank you for your support,

John F. Lewis, Jr.

President & CEO, BioOhio